As of June 30, 2026, enVVeno Medical Corporation carries a market capitalization of 7.02M, placing it among publicly traded companies globally. Its enterprise value stands at -13.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.02M |
| Enterprise Value | -13.96M |
enVVeno Medical Corporation's next confirmed earnings release is scheduled for March 4, 2027.
| Earnings Date | 3/4/2027 |
As of June 30, 2026, enVVeno Medical Corporation has 655,521.00 shares outstanding.
| Shares Outstanding | 655,521.00 |
These figures are as of June 30, 2026.
| PB Ratio | 0.34 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | -0.46 |
| P/OCF Ratio | -0.46 |
As of June 30, 2026, enVVeno Medical Corporation maintains a current ratio of 11.70, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.70 |
| Quick Ratio | 11.39 |
| Debt / Equity | 2.44 |
| Debt / EBITDA | -0.03 |
Over the twelve months ended June 30, 2026, enVVeno Medical Corporation posted a negative return on equity (ROE) of -58.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -53.09, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 34.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -58.53 |
| Return on Assets (ROA) | -53.09 |
| Employee Count | 34.00 |
As of the close on November 16, 2026, enVVeno Medical Corporation's stock has declined approximately 59.56% over the past 52 weeks. The 50-day moving average sits at 8.00, while the 200-day moving average is 10.06.
| 52-Week Price Change | -59.56% |
| 50-Day Moving Average | 8.00 |
| 200-Day Moving Average | 10.06 |
Over the twelve months ended June 30, 2026, enVVeno Medical Corporation generated - - in revenue and converted that into -15.72M in net income, yielding earnings per share of -24.83. EBITDA reached -16.36M, while operating income came in at -16.75M.
| Operating Income | -16.75M |
| Pretax Income | -15.72M |
| Net Income | -15.72M |
| EBITDA | -16.36M |
| EBIT | -16.75M |
| Earnings Per Share (EPS) | -24.83 |
As of June 30, 2026, enVVeno Medical Corporation holds 21.49M in cash and equivalents against 505,000.00 in total debt, resulting in a net debt position of -2.84M. Total book value stands at 20.67M, with working capital of 20.20M providing operational flexibility.
| Cash & Cash Equivalents | 21.49M |
| Total Debt | 505,000.00 |
| Net Debt | -2.84M |
| Equity (Book Value) | 20.67M |
| Book Value Per Share | 31.53 |
| Working Capital | 20.20M |
enVVeno Medical Corporation produced -14.62M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -14.62M - equivalent to -23.09 per share.
| Operating Cash Flow | -14.62M |
| Free Cash Flow | -14.62M |
| FCF Per Share | -23.09 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -215.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -215.59 |
enVVeno Medical Corporation's most recent stock split took place on January 20, 2026 with a 35:1 split ratio.
| Last Split Date | 1/20/2026 |
| Split Ratio | 35:1 |
As of June 30, 2026, enVVeno Medical Corporation has an Altman Z-Score of -10.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -10.30 |